title: Patterns of TH1/TH2 cytokines predict clinical response in multiple sclerosis patients treated with glatiramer acetate.
abstract: The patterns of Th1/Th2 cytokines in relapsing-remitting multiple sclerosis were analyzed to evaluate their relevance as biomarkers of therapy response to glatiramer acetate (GA). Serum interferon-γ (IFN-γ), osteopontin and interleukin (IL)-2, IL-4, and IL-10 were measured in 19 relapsing-remitting multiple sclerosis patients treated with GA in a prospective study over 3 years. The quotient (IL-2 + IFN-γ)/(IL-4 + IL-10) was elevated in patients with relapses as compared to relapse-free patients after 12 (p = 0.04), 24 (p = 0.02) and 36 months (p = 0.04). Our study indicates that specific patterns of Th1/Th2 cytokines predict the response to GA therapy.
authors.affiliation: Department of Neurology, University of Ulm, Oberer Eselsberg 45, Ulm, Germany. hayrettin.tumani@uni-ulm.de
authors.forename: Hayrettin
authors.initials: H
authors.lastname: Tumani
authors.forename: Jan
authors.initials: J
authors.lastname: Kassubek
authors.forename: Mohammed
authors.initials: M
authors.lastname: Hijazi
authors.forename: Vera
authors.initials: V
authors.lastname: Lehmensiek
authors.forename: Alexander
authors.initials: A
authors.lastname: Unrath
authors.forename: Sigurd
authors.initials: S
authors.lastname: Süssmuth
authors.forename: Florian
authors.initials: F
authors.lastname: Lauda
authors.forename: Tamara
authors.initials: T
authors.lastname: Kapfer
authors.forename: Lubin
authors.initials: L
authors.lastname: Fang
authors.forename: Makbule
authors.initials: M
authors.lastname: Senel
authors.forename: Johannes
authors.initials: J
authors.lastname: Brettschneider
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D001921:Brain / Q000473:pathology; D016207:Cytokines / Q000097:blood*; D005260:Female; D000068717:Glatiramer Acetate; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D010455:Peptides / Q000627:therapeutic use*; D018417:Th1 Cells / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D000276:Adjuvants, Immunologic; D016207:Cytokines; D010455:Peptides; D000068717:Glatiramer Acetate